GlassScriptPhysician profile
Nazia Khan
NPI 1700196581
$4,387.47
in general payments reported to CMS, 2019-2025
36 companies · $261 in 2025
The $261 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $302 · 2021: $585 · 2022: $834 · 2023: $785 · 2024: $1,497 · 2025: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $1,196 · Food and Beverage: $1,167 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $1,196.40 |
| Food and Beverage | $1,167.11 |
| Education | $179.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,428.79 | 2021-2024 | |
| Seagen INC. | $334.55 | 2020-2025 | Tukysa, Padcev |
| Mirati Therapeutics, INC. | $294.58 | 2023-2024 | Krazati |
| Amgen INC. | $249.45 | 2020-2023 | Lumakras |
| E.R. Squibb & Sons, L.L.C. | $236.45 | 2021-2023 | Reblozyl |
| Merck Sharp & Dohme LLC | $161.95 | 2021-2024 | Welireg, Keytruda |
| Astrazeneca Pharmaceuticals LP | $150.01 | 2020-2024 | Lynparza |
| Janssen Biotech, INC. | $148.29 | 2022-2025 | Erleada |
| Pharmacyclics LLC, An Abbvie Company | $130.60 | 2020-2022 | |
| Daiichi Sankyo INC. | $126.27 | 2020-2023 | Enhertu |
| Boston Scientific Corporation | $123.10 | 2019 | |
| Pfizer INC. | $119.39 | 2022-2024 | |
| Genzyme Corporation | $85.47 | 2021-2025 | |
| Karyopharm Therapeutics INC. | $78.40 | 2022-2023 | Xpovio |
| Celgene Corporation | $76.13 | 2022-2024 | Reblozyl, Pomalyst |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $75.00 | 2021-2024 | |
| Lilly USA, LLC | $65.29 | 2020-2024 | Retevmo, Jaypirca, Verzenio |
| Myriad Genetic Laboratories, INC. | $59.53 | 2023-2024 | Myrisk |
| Astellas Pharma US INC | $53.13 | 2021-2023 | Xospata |
| Caris Mpi, INC. | $45.67 | 2025 | Mi Cancer Seek |
| Regeneron Healthcare Solutions, INC. | $44.32 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.03 | 2022-2023 | Ninlaro |
| Gilead Sciences, INC. | $34.41 | 2024 | |
| Incyte Corporation | $28.53 | 2021-2022 | |
| Exelixis INC. | $28.08 | 2021-2022 | |
| Immunogen, INC. | $21.13 | 2024 | Elahere |
| Cumberland Pharmaceuticals, INC. | $19.00 | 2025 | Sancuso |
| Argenx US, INC. | $18.88 | 2024 | Vyvgart Hytrulo |
| Abbvie INC. | $16.76 | 2022 | |
| Genmab U.S., INC. | $15.65 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.98 | 2021 | |
| Taiho Oncology, INC. | $14.75 | 2022 | |
| Morphosys, US INC. | $14.27 | 2022 | |
| Rigel Pharmaceuticals, INC. | $13.64 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.33 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nazia Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.